Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2015

View Archived Issues

[11C]PF-367: a promising PET tracer for neuroimaging of GSK-3

Phase I/IIa results disclosed for therapeutic p16 HPV vaccine

Sareum secures funding to investigate TYK2 inhibitors for T-ALL

INV-17, a RORgT inverse agonist, demonstrates complete survival in MRL/lpr mice

GenSpera receives grant from FDA OOPD to develop mipsagargin for glioblastoma

Synergy Pharmaceuticals reports phase III results for plecanatide in CIC

Merck & Co. discloses Nav1.7 sodium channel blockers

Chong Kung Dang presents GPR119 agonists

Kyorin introduces FPR2 agonists

Nektar Therapeutics discloses opioid agonists

Incyte develops BRD4 inhibitors

Actavis adopts Allergan name

Clinical benefit seen with autologous T cells specific for HER2 and CMV in glioblastoma multiforme

HemoShear changes name to reflect new focus on discovery of novel therapeutics

Biosimilar etanercept SB-4 found equivalent in phase III study in RA

Velicept to merge with AltheRx to advance development of solabegron

Merck KGaA's acquisition of Sigma-Aldrich cleared by EC and Chinese authorities

Lilly forges new oncology collaborations

FDA approves Ventana's companion diagnostic test for Xalkori

University of Queensland to lead project on MERS

Genentech and Almac Discovery to develop ubiquitin-specific protease inhibitors

Radius Health reports results from phase III trials of abaloparatide in osteoporosis

First clinical data of namilumab in patients with active RA

FORMA Therapeutics achieves milestones under agreements with Celgene and Boehringer Ingelheim

Improvement in growth velocity observed in phase II study of BMN-111 for achondroplasia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 20, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 20, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...